Your session is about to expire
← Back to Search
Gemcitabine Hydrochloride for Pancreatic Cancer
Study Summary
This trial is testing pembrolizumab, paricalcitol, and chemotherapy as a possible treatment for pancreatic cancer before surgery.
- Pancreatic Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the cap on the number of participants in this clinical evaluation?
"This trial is not actively recruiting participants. It was first listed on February 20th 2017 and last updated September 22nd 2022. If you're looking for alternatives, there are currently 580 trials specifically seeking patients with pancreatic carcinoma and 1981 studies enrolling those interested in receiving Pembrolizumab treatment."
Are there currently vacancies available for participants of this trial?
"The latest update on clinicaltrials.gov reveals that this medical trial is not presently recruiting patients; it was initially posted in February of 2017 and its last modification occurred in September 2022. Nonetheless, there are over two-thousand five hundred sixty one other studies actively seeking participants at the present moment."
Has Pembrolizumab received the regulatory stamp of approval from the FDA?
"The safety of Pembrolizumab is estimated to be a 1, as the current trial stage only provides minimal data supporting its efficacy and security."
What is the primary condition that Pembrolizumab has been shown to alleviate?
"Pembrolizumab is a commonly-prescribed medication for mesotheliomas and other diseases, such as metastatic esophageal carcinoma, hemodialysis, or advanced soft tissue sarcoma."
Are there any antecedent investigations related to Pembrolizumab?
"Currently, there are 1981 Pembrolizumab-focused trials occurring worldwide. Of those studies, 415 of them have reached the third phase and can be found in Shanghai as well as 85517 other locations."
Share this study with friends
Copy Link
Messenger